Amalgamated Bank Has $3 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Amalgamated Bank increased its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 8.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,397 shares of the biopharmaceutical company’s stock after acquiring an additional 4,099 shares during the quarter. Amalgamated Bank owned about 0.05% of Cytokinetics worth $3,001,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. E Fund Management Co. Ltd. increased its holdings in shares of Cytokinetics by 141.6% during the 2nd quarter. E Fund Management Co. Ltd. now owns 15,927 shares of the biopharmaceutical company’s stock worth $863,000 after purchasing an additional 9,336 shares during the period. Mutual of America Capital Management LLC grew its position in Cytokinetics by 12.3% during the second quarter. Mutual of America Capital Management LLC now owns 65,645 shares of the biopharmaceutical company’s stock worth $3,557,000 after buying an additional 7,208 shares in the last quarter. Edgestream Partners L.P. bought a new position in Cytokinetics during the second quarter valued at about $858,000. Renaissance Technologies LLC raised its holdings in Cytokinetics by 28.7% in the 2nd quarter. Renaissance Technologies LLC now owns 470,967 shares of the biopharmaceutical company’s stock valued at $25,517,000 after acquiring an additional 105,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Cytokinetics by 27.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 148,561 shares of the biopharmaceutical company’s stock worth $8,049,000 after acquiring an additional 32,372 shares during the period.

Cytokinetics Stock Down 3.1 %

NASDAQ:CYTK opened at $52.09 on Tuesday. The company has a market cap of $5.46 billion, a price-to-earnings ratio of -9.65 and a beta of 0.77. The company has a debt-to-equity ratio of 5.93, a quick ratio of 10.39 and a current ratio of 10.39. The stock’s fifty day moving average price is $56.11 and its two-hundred day moving average price is $59.09. Cytokinetics, Incorporated has a 52-week low of $25.98 and a 52-week high of $110.25.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.25). The company had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $7.61 million. During the same period last year, the firm posted ($1.34) EPS. The firm’s revenue for the quarter was down 71.3% on a year-over-year basis. On average, analysts anticipate that Cytokinetics, Incorporated will post -5.15 EPS for the current year.

Wall Street Analysts Forecast Growth

CYTK has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Cytokinetics in a research report on Friday. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a report on Wednesday, September 4th. B. Riley lowered their target price on shares of Cytokinetics from $122.00 to $92.00 and set a “buy” rating on the stock in a research note on Tuesday, June 4th. JPMorgan Chase & Co. raised their price target on shares of Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a research note on Thursday, September 5th. Finally, The Goldman Sachs Group lowered Cytokinetics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $85.00 to $60.00 in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Insider Activity at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 11,500 shares of Cytokinetics stock in a transaction on Monday, July 1st. The shares were sold at an average price of $54.05, for a total transaction of $621,575.00. Following the completion of the sale, the chief executive officer now owns 405,145 shares of the company’s stock, valued at approximately $21,898,087.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Robert I. Blum sold 11,500 shares of Cytokinetics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $54.05, for a total transaction of $621,575.00. Following the completion of the sale, the chief executive officer now directly owns 405,145 shares of the company’s stock, valued at $21,898,087.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $57.03, for a total value of $285,150.00. Following the completion of the transaction, the chief executive officer now directly owns 397,456 shares in the company, valued at approximately $22,666,915.68. The disclosure for this sale can be found here. Insiders have sold 100,537 shares of company stock worth $5,626,227 over the last ninety days. Company insiders own 3.40% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.